SpikImm, co-founded by Truffle Capital and Institut Pasteur is a clinical-stage biopharma company that develops mAbs for the prevention of severe infectious diseases affecting immunocompromised (IC) patients. SpikImm’s portfolio include SPK002M, a highly potent mAb active across all existing SARS-CoV-2 variants. SpikImm is currently expanding its portfolio with additional anti-infective mAbs, also developed in prevention of infectious diseases affecting immunocompromised patients.
See websiteSynoptical view
- First investment date
- 2021